Prevention of adenocarcinoma in situ caused by HPV types 16 and 18, Prevention of cervical cancer caused by HPV types 16 and 18, Prevention of cervical intraepithelial neoplasia (CIN), CIN 1 and pre-cancerous lesions (CIN 2 and 3) caused by HPV types 16 and 18
Adult: Females: 0.5 mL given at 0, 1, and 6 months. If flexibility in the schedule is needed, may administer 2nd and 3rd doses within 3-12 months after the 1st dose.
Child: Females: 9-14 years 2 doses each of 0.5 mL. May administer 2nd dose between 5 and 13 months after the 1st dose; ≥15 years Same as adult dose.
Child: Females: 9-14 years 2 doses each of 0.5 mL. May administer 2nd dose between 5 and 13 months after the 1st dose; ≥15 years Same as adult dose.